Source comparison
Cardiac Biology: CD36-Dependent Hexarelin Cardioprotection vs CJC-1295 Indirect Effects
The most dramatic mechanistic divergence between Hexarelin and CJC-1295 lies in cardiac biology. Hexarelin produces direct, GH-independent cardioprotection via CD36. In hypophysectomised (pituitary-ablated) rats — eliminating all GH production — Hexarelin at 8
This comparison does not assign a generated winner or score.
- The most dramatic mechanistic divergence between Hexarelin and CJC-1295 lies in cardiac biology. Hexarelin produces direct, GH-independent cardioprotection via CD36. In hypophysectomised (pituitary-ablated) rats — eliminating all GH production — Hexarelin at 80 µg/kg iv before LAD coronary artery occlusion/reperfusion reduces infarct size by 32–38% of AAR (area at risk), and LVEF improves from 34 ± 3% (vehicle) to 44 ± 4% at day 7. This protection is abolished by anti-CD36 neutralising antibody (68–72% block) and by PI3K inhibitor wortmannin (62–68%) — confirming CD36-PI3K-Akt-eNOS as the operating pathway and excluding GH-IGF-1 as the mechanism.
- In intact (pituitary-replete) animals, Hexarelin’s cardiac protection is amplified: total infarct reduction reaches 44–52%, with GHS-R1a contributing an estimated 32–38% and CD36 the remaining 12–14%. The two pathways appear partially additive in cardiac tissue.
- CJC-1295 produces no direct cardiac CD36 or GHS-R1a activity. Its cardiac effects are indirect and GH-IGF-1-mediated: in post-MI C57BL/6J mice receiving CJC-1295 non-DAC at 10 µg/kg 3×/week for 4 weeks, LVEF improves from 38 ± 3% to 44 ± 4% — an effect blocked by IGF-1R antibody (68–72%), confirming IGF-1R-mediated cardiomyocyte survival as the mechanism. The onset is delayed (day 7–14) versus Hexarelin’s acute (day 1–3) protection, reflecting the GH→IGF-1 lag.
- The clinical research implication: acute cardiac ischaemia-reperfusion experiments require Hexarelin for direct CD36-mediated protection studies. Chronic cardiac remodelling research (post-infarct ventricular function, cardiomyopathy) may employ either compound, with CJC-1295 preferred when isolating the GH-IGF-1 cardiac axis without cortisol confounding.
- 🔗 Related Reading: For Hexarelin’s full cardiac and GHS-R1a biology, see our Hexarelin UK Research Guide.